Case: Maculaser – a Health Tech case from Aalto Innovation Services and Spark Finland is going to facilitate the workshop “How to build a value proposition canvas for startups & innovation projects”.

Benefits for you at the workshop: You will learn and hear new things from the Maculaser case for the health tech sector, and also find out how you can make your own value proposition canvas for your business. Amanda Paananen from Spark Finland will help to implement the strategy canvas for ideas as well as small and large businesses.

Content is relevant to CEOs, business developers, sales and marketing people, investors, partners and startups and to those in both the private and public sectors of healthcare. We have three experienced professional speakers for you; Jani Tirronen from Maculaser , Amanda Paananen from Spark Finland and Tuomas Planman from Aalto Innovation Services. You will get to know to an unique health tech case from Aalto Innovation Services and at the same time you can find out some things for your own business. From Ideas To Impact ™ See you there!

What is Maculaser?

Maculaser – Novel Therapy for Age-related Macular Degeneration. The company vision is to enable millions of previously untreatable AMD patients to retain their vision.

The project develops novel medical technology for the treatment of common eye-disease, AMD, whose treatment constitutes a major unmet need in the medical field: It is the leading cause of blindness in the developed world, with total direct healthcare system cost of 200 billion euros annually.

Our innovations allow clinicians to perform previously infeasible laser therapy and help millions of people to retain their vision.

Maculaser started as a Business Finland and Aalto University funded commercialization research project in the summer of 2018. Maculaser is a team of 5 people and they are currently looking for funding for clinical trials and building the first commercial product.

Fig. 1 DRY AMD – LOSS OF RPE AND PHOTORECEPTORS
  • The macula is located near the center of the retina of the human eye and is responsible for the central, high-resolution, vision
  • In late stages of dry AMD, there is loss in RPE (Figure) and photoreceptors in the macula, leading to atrophy, tissue death and visual disturbance in the central visual field
  • Non-damaging laser treatments stimulate the natural healing response of the eye and stop this degeneration in earlier stages of AMD.

”Age-related macular degeneration is a degenerative retinal disease that causes a progressive loss of central vision. There are currently 200 million people living with AMD. At present, there is no effective treatment for dry AMD, which is the most common form of the disease, and no means to prevent the disease from progressing to its quickly blinding wet form. Our goal is to develop technology that enables AMD treatment already in its early stages. In our treatment, we apply heat to the fundus of the eye with an ophthalmic laser where the challenge lies in reaching the narrow therapeutic temperature window reliably. Our novel technology innovation allows us to control the thermal dose on fundus individually which makes the treatment effective, safe and non-invasive,” said Teemu Turunen from Maculaser.

See you on the 6th of June at Arctic15! Don’t miss this talk from a top high-level case in the health tech sector with strategy work with a value proposition canvas.

Teemu has ten years of experience from vision research and technical development of electrophysiological methods from his earlier career and PhD project. Additionally, Teemu has worked as an innovation agent with the responsibility of scouting for potential innovations and assisting with IPR issues in Aalto University. Maculaser project manager, Teemu Turunen, M.Sc.